secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2024-09-05T23:59:59+00:00
Accession:  0001193125-24-214188
Event type: regulatory
Sentiment:  positive
Materiality: 0.45
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Therapeutics regains Nasdaq minimum bid price compliance
---------------------------------------------------------------

- Received Nasdaq letter on Sept 3, 2024 confirming compliance with Minimum Bid Price Requirement.
- Previous deficiency letter was dated Sept 5, 2023; stock had closed below $1.00 for 30 consecutive days.
- Compliance achieved under Nasdaq Listing Rules 5450(a)(1) and 5550(a)(2); matter is closed.
- No additional financial or operational details provided in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000119312524214188/0001193125-24-214188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000119312524214188/d857897d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-214188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer